Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis

Li, Xing; Gu, Lijiang; Chen, Yuhang; Chong, Yue; Wang, Xinyang; Guo, Peng; He, Dalin

doi:10.1080/07853890.2021.1991591

Cited by 44 publications

(33 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A higher SII corresponds to higher platelet/neutrophil and/or lower lymphocyte counts. Thus, an elevated SII indirectly symbolizes the deficiency of immune function and the enhancement of tumor aggressiveness in cancer patients ( 32 ). As a composite immune index, SII may have better predictive power than parameters such as NLR, PLR, and LMR.…”

Section: Discussionmentioning

confidence: 99%

The Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Bladder Cancer

Cao

Huang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundSystemic immune-inflammation index (SII) has recently emerged as a biomarker for the prognosis of a variety of malignant tumors. However, the role of SII in bladder cancer (BC) remains unclear. To this end, we performed a pooled analysis to investigate the prognostic value of preoperative SII in patients with BC.MethodsA comprehensive search of electronic databases (PubMed/Medline, Web of Science, Scopus, and Cochrane Central Register of Controlled Trials) was conducted to determine the eligible studies that were published until January 2022. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the association between preoperative SII and the prognosis and clinicopathological characteristics of BC.ResultsTen studies with 7,087 patients were included in this analysis. SII was observed to be correlated with inferior overall survival (HR = 1.22, 95% CI 1.04–1.44, p = 0.013), cancer-specific survival (HR = 1.68, 95% CI 1.14–2.47, p = 0.009), and recurrence-free survival (HR = 1.29, 95% CI 1.03–1.61, p = 0.027). An increased preoperative SII was also associated with poor tumor differentiation, higher tumor stage, presence of lymph node involvement, and tumor size ≥3 cm (all p < 0.05).ConclusionsAn elevated preoperative SII is significantly associated with worse survival outcomes and adverse pathological features in patients with BC. Hence, SII may serve as a strong independent prognostic predictor for patients with BC after surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

The Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Bladder Cancer

Cao

Huang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…First, Zhang et al [ 33 ] suggested that a high SII was related to poor prognosis in breast cancer patients and clinicopathological features that indicated tumor progression. Additionally, Li et al [ 34 ] reported that SII could serve as a promising noninvasive biomarker to assess the prognosis of patients with urinary system cancer. Another meta-analysis showed that a higher pre-treatment SII was significantly associated with poorer survival outcomes and several clinical characteristics in GC [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of systemic immune-inflammation index in patients with nasopharyngeal carcinoma: a meta-analysis

Zeng

Wang

et al. 2022

Syst Rev

View full text Add to dashboard Cite

Background Previous studies have investigated the prognostic value of the systemic immune-inflammation index (SII) in nasopharyngeal carcinoma (NPC). However, the results have been inconsistent. Therefore, this study aims to investigate the prognostic significance of SII in NPC through a meta-analysis. Methods The PubMed, Web of Science, Embase, and Cochrane Library databases were thoroughly searched. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the prognostic value of the SII for survival outcomes. Results A total of six studies comprising 2169 patients were included in the meta-analysis. Pooled analyses indicated that a high SII was significantly associated with worse overall survival (OS) (HR = 1.69, 95% CI = 1.36–2.09, P < 0.001) and progression-free survival (PFS) (HR = 1.60, 95% CI = 1.29–1.98, P < 0.001) in patients with NPC. Subgroup analysis showed that SII was a significant prognostic marker for PFS but not for OS in NPC. Conclusion Our meta-analysis demonstrated that a high SII could be an efficient prognostic indicator of OS and PFS in NPC. In our opinion, SII could be used to predict long-term and short-term outcomes in patients with NPC. Furthermore, we suggest that SII be applied to help individual patients with NPC assess the prognostic risk. Systematic review registration PROSPERO CRD42022321570

show abstract

“…It has been also suggested that as the SII includes three different cells, it may better reflect the inflammatory status than other indices, which are typically based on two cells such as NLR and PLR or the lymphocyte-to-monocyte ratio. The first study on SII reported that it strongly predicted poor prognosis in several types of gastrointestinal and other systems malignancies [ 42 ]. Following these studies, the association between the SII and cardiovascular diseases has been increasingly investigated.…”

Section: Discussionmentioning

confidence: 99%

The Systemic Immune-Inflammation Index May Predict the Coronary Slow Flow Better Than High-Sensitivity C-Reactive Protein in Patients Undergoing Elective Coronary Angiography

Karaüzüm

Hanci

et al. 2022

Cardiology Research and Practice

View full text Add to dashboard Cite

Background and Objectives. The coronary slow flow (CSF) is an angiographic finding characterized by delayed opacification of nonobstructive epicardial coronary arteries. Chronic inflammation has been suggested to be mainly responsible for the underlying mechanism of CSF. The systemic immune-inflammation index (SII) is a relatively novel inflammation-based biomarker, derived from counts of peripheral neutrophils, platelets, and lymphocytes, and has been shown to predict clinical outcomes in various malignancies and cardiovascular diseases. The aim of this study is to evaluate the relationship between SII and CSF. Methods. A total of 197 patients (102 patients with CSF; 95 patients with normal coronary flow) were included in this retrospective study. Clinical and angiographic characteristics of patients were obtained from hospital records. Results. Patients with CSF had higher SII, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR), and high-sensitivity C-reactive protein (hsCRP) levels compared with the control group. Body mass index ( p = 0.022 , OR 1.151, 95% CI 1.121–1.299), low-density lipoprotein ( p = 0.018 , OR 1.028, 95% CI 1.005–1.052), hsCRP ( p = 0.044 , OR 1.161, 95% CI 1.004–1.343), and SII ( p < 0.001 , OR 1.015, 95% CI 1.003–1.026) were independent predictors of CSF in the multivariable analysis. The optimal cutoff value of SII in predicting CSF was >877 in ROC curve analysis ( p < 0.001 , AUC = 0.892, 95% CI 0.848–0.936). This cutoff value of SII predicted the CSF with a sensitivity of 71.5% and specificity of 92.4%. Spearman correlation analysis showed a positive correlation between the mean TFC value and PLR, NLR, hsCRP, and SII. Conclusions. SII may be used as a better indicator for the prediction of CSF than hsCRP.

show abstract

Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis

Cited by 44 publications

References 46 publications

The Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Bladder Cancer

The Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Bladder Cancer

Prognostic significance of systemic immune-inflammation index in patients with nasopharyngeal carcinoma: a meta-analysis

The Systemic Immune-Inflammation Index May Predict the Coronary Slow Flow Better Than High-Sensitivity C-Reactive Protein in Patients Undergoing Elective Coronary Angiography

Contact Info

Product

Resources

About